U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H18NO2.Cl
Molecular Weight 195.687
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHACHOLINE CHLORIDE

SMILES

[Cl-].CC(C[N+](C)(C)C)OC(C)=O

InChI

InChIKey=JHPHVAVFUYTVCL-UHFFFAOYSA-M
InChI=1S/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H18NO2
Molecular Weight 160.234
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546

Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
PROVOCHOLINE

Approved Use

Provocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma.

Launch Date

1986
Doses

Doses

DosePopulationAdverse events​
16 mg/mL 5 times / day multiple, respiratory (max)
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bronchial airway hyperreactivity
Sources: Page: p.1
Disc. AE: Bronchoconstriction...
AEs leading to
discontinuation/dose reduction:
Bronchoconstriction (severe)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Bronchoconstriction severe
Disc. AE
16 mg/mL 5 times / day multiple, respiratory (max)
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bronchial airway hyperreactivity
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Noninvasive method to measure airway obstruction in nonanesthetized allergen-sensitized and challenged mice.
2001
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man.
2001
Airway foreign body with clinical features mimicking bronchial asthma.
2001
Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen.
2001 Apr
Changes in indices of airway hyperresponsiveness during one year of treatment with inhaled corticosteroids in patients with asthma.
2001 Apr
Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma.
2001 Apr
Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways.
2001 Apr
Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families.
2001 Apr
Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity.
2001 Apr
Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma.
2001 Apr
Effects of smooth muscle activation on axial mechanical properties of excised canine bronchi.
2001 Apr
Hexachlorobenzene-induced eosinophilic and granulomatous lung inflammation is associated with in vivo airways hyperresponsiveness in the Brown Norway rat.
2001 Apr 1
Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2).
2001 Apr 15
Respiratory effects of a single dive to 50 meters in sport divers with asymptomatic respiratory atopy.
2001 Feb
G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.
2001 Feb
The lack of the bronchoprotective and not the bronchodilatory ability of deep inspiration is associated with airway hyperresponsiveness.
2001 Feb
Protective effects of volatile agents against methacholine-induced bronchoconstriction in rats.
2001 Feb
Blockade of eosinophil migration and airway hyperresponsiveness by cPLA2-inhibition.
2001 Feb
Endotoxin responsiveness and subchronic grain dust-induced airway disease.
2001 Feb
Impaired endothelium-dependent vasodilatation in renal failure in humans.
2001 Feb
Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis.
2001 Jan
Methacholine inhalation challenge: a shorter, cheaper and safe approach.
2001 Jan
ATS guidelines for methacholine and exercise challenge testing.
2001 Jan
Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.
2001 Jan
Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma.
2001 Jan
Linkage between bronchial responsiveness to methacholine and gene markers of IL-4 cytokine gene cluster and T-cell receptor alpha/delta gene complex in Korean nuclear families.
2001 Jan
[Asthma related to inhalation of Plantago ovata].
2001 Jan 13
Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung.
2001 Jun
SCF-induced airway hyperreactivity is dependent on leukotriene production.
2001 Jun
Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle.
2001 Jun
Regulation of secretion from mucous and serous cells in the excised ferret trachea.
2001 Jun
Effects of BCG on ovalbumin-induced bronchial hyperreactivity in a guinea pig asthma model.
2001 Mar
Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum.
2001 Mar
High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma.
2001 Mar
Incidence and host determinants of probable occupational asthma in apprentices exposed to laboratory animals.
2001 Mar
Measurements of resistance by the interrupter technique and of transcutaneous partial pressure of oxygen in young children during methacholine challenge.
2001 Mar
Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha).
2001 Mar
The transcription factor early growth-response factor 1 modulates tumor necrosis factor-alpha, immunoglobulin E, and airway responsiveness in mice.
2001 Mar
Drug treatment of airway inflammation in asthma.
2001 Mar
Polycystic ovary syndrome is associated with endothelial dysfunction.
2001 Mar 13
Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans.
2001 Mar 27
Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle.
2001 Mar 9
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus.
2001 May
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model.
2001 May
Occupational asthma caused by exposure to cyanoacrylate.
2001 May
Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults.
2001 May
Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients.
2001 May
Incidence of sensitization, symptoms, and probable occupational rhinoconjunctivitis and asthma in apprentices starting exposure to latex.
2001 May
Inhibition of m3 muscarinic acetylcholine receptors by local anaesthetics.
2001 May
Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans.
2001 May
Patents

Sample Use Guides

Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration: Respiratory
In Vitro Use Guide
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:48 GMT 2023
Edited
by admin
on Fri Dec 15 16:35:48 GMT 2023
Record UNII
0W5ETF9M2K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHACHOLINE CHLORIDE
INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
NSC-757090
Code English
METHACHOLINE CHLORIDE [MART.]
Common Name English
METHACHOLINE CHLORIDE [USP-RS]
Common Name English
Methacholine chloride [WHO-DD]
Common Name English
(±)-(2-HYDROXYPROPYL)TRIMETHYLAMMONIUM CHLORIDE ACETATE
Systematic Name English
METHACHOLINE CHLORIDE [JAN]
Common Name English
METHACHOLINE CHLORIDE [USP MONOGRAPH]
Common Name English
METHACHOLINE CHLORIDE [VANDF]
Common Name English
1-PROPANAMINIUM, 2-(ACETYLOXY)-N,N,N-TRIMETHYL-, CHLORIDE, (±)-
Systematic Name English
METHACHOLINE CHLORIDE [MI]
Common Name English
methacholine chloride [INN]
Common Name English
PROVOCHOLINE
Brand Name English
METHACHOLINE CHLORIDE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1937
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
Code System Code Type Description
RXCUI
40165
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY RxNorm
EVMPD
SUB08832MIG
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
DAILYMED
0W5ETF9M2K
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
NCI_THESAURUS
C47607
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
RS_ITEM_NUM
1396364
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID7023271
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
INN
3161
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-537-2
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL978
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
MESH
D016210
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
CAS
62-51-1
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
PUBCHEM
6114
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
MERCK INDEX
m7282
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY Merck Index
DRUG BANK
DBSALT001175
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
FDA UNII
0W5ETF9M2K
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
NSC
757090
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
SMS_ID
100000081225
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
CHEBI
50142
Created by admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
USP
IMPURITY -> PARENT
USP
Related Record Type Details
ACTIVE MOIETY